Trial · NCT07911995
A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
NCT07911995, Phase 2, Not yet recruiting, Grünenthal GmbH
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy. Trials, record NCT07911995. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911995
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
- NCT number
- NCT07911995
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 36 participants, estimated
- Lead sponsor
- Grünenthal GmbH
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Tegacorat
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Core Phase: Change From Baseline in Time-to-Stand-from-Supine (TTSTAND) Velocity | Baseline to Week 24 | Change from baseline to Week 24 in TTSTAND velocity. |
| Primary | Extension Phase: Incidence of Adverse Events | First dose through Week 96 | Safety and Tolerability. |
| Secondary | Core Phase: Change From Baseline in Stride Velocity 95th Centile (SV95C) | Baseline to Week 24 | Change from baseline to Week 24 in SV95C measured using wearable sensor technology. |
| Secondary | Core Phase: Change From Baseline in 10-Meter Walk/Run (10MWR) velocity | Baseline to Week 24 | Change From Baseline in Functional Test Performance. |
| Secondary | Core Phase: Change From Baseline in Time-to-Climb-4-Stairs (TTCLIMB) velocity | Baseline to Week 24 | Change From Baseline in Functional Test Performance. |
| Secondary | Core Phase: Incidence of Adverse Events | First dose through Week 24 | Safety and Tolerability. |
| Secondary | Extension Phase: Time to Treatment Discontinuation Due to Adverse Events | Up to Week 96 | Time to permanent discontinuation of study treatment due to an adverse event. |
| Secondary | Extension Phase: Change From Baseline in Weight and BMI Z-Scores | Baseline to Week 96 | Change from baseline in weight and body mass index (BMI) Z-scores. |
| Secondary | Extension Phase: Change From Baseline in Cushingoid Features | Baseline to Week 96 | Change from baseline in Cushingoid features. |
| Secondary | Extension Phase: Change From Baseline in Glucose Metabolism | Baseline to Week 96 | Change from baseline in fasting glucose and fasting serum insulin. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911995
GET https://conductscience.org/api/trials/v1/NCT07911995/registered